Welcome to our dedicated page for Akoya Biosciences SEC filings (Ticker: AKYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Akoya Biosciences, Inc. (AKYA) provides access to the company’s historical regulatory documents, including reports that detail its operations as a public company and the corporate actions that led to its acquisition by Quanterix Corporation. These filings cover financial statements, risk disclosures, and material events related to Akoya’s role as The Spatial Biology Company®, offering single-cell imaging and spatial proteomics solutions for discovery, translational, and clinical research.
Investors can review periodic reports such as Forms 10-K and 10-Q (where available) to understand how Akoya described its revenue composition between product and service activities, its installed base of instruments, and the growth in publications citing its technology. These documents also typically include discussions of research collaborations, market focus in spatial biology and immuno-oncology, and factors affecting operations and funding.
Material event filings on Form 8-K are especially important for understanding Akoya’s corporate trajectory. A Form 8-K filed on July 8, 2025 explains that Akoya completed the transactions under the Amended and Restated Agreement and Plan of Merger with Quanterix, with Wellfleet Merger Sub, Inc. merging into Akoya and Akoya surviving as a wholly owned subsidiary of Quanterix. The filing outlines the merger consideration structure, the treatment of equity awards, the repayment and termination of Akoya’s credit agreement, and changes in control, governance, and key corporate agreements.
For trading status, a Form 25 filed on July 8, 2025 by the Nasdaq Stock Market LLC notifies the SEC of the removal of Akoya’s common stock from listing and registration on the Nasdaq Global Select Market. Akoya’s Form 8-K further notes its intention to file a Form 15 to terminate the registration of its common stock and suspend reporting obligations under the Exchange Act. Together, these filings document the transition of AKYA from a Nasdaq-listed security to the equity of a wholly owned subsidiary within Quanterix.
On this page, AI-powered tools can help users interpret complex filings by summarizing key points from lengthy documents such as merger agreements, 10-Ks, and 10-Qs. These summaries can highlight items like revenue breakdowns, major collaborations, capital structure changes, and the specific terms and implications of the Quanterix merger, aiding investors and researchers who are examining AKYA’s historical regulatory record.
The filing is a Post-Effective Amendment to five prior Form S-8 registration statements covering an aggregate approximately 15.4 million shares of Akoya Biosciences common stock reserved for issuance under the company’s 2015 and 2021 equity and ESPP plans. On 8 July 2025 Akoya completed its previously announced merger with Quanterix Corporation, becoming a wholly owned subsidiary. Because the merger terminated any further offering of Akoya securities, the company is using this amendment to withdraw and remove from registration all unissued shares under the referenced S-8s. No new securities are being registered, and the filing contains no financial results, capital raising, or operational updates. The sole signatory is Treasurer Vandana Sriram pursuant to Rule 478.
For investors, this action is largely administrative and neutral: it formally closes out equity incentive plans that ceased to exist once Akoya was acquired. The amendment neither affects Quanterix’s share count nor provides insight into the financial performance of either company.
Akoya Biosciences, Inc. (AKYA) filed Post-Effective Amendment No. 1 to five prior Form S-8 registration statements that collectively covered roughly 15.4 million shares reserved for the company’s 2015 and 2021 equity incentive and employee stock purchase plans. The amendment withdraws and removes from registration all shares that remained unissued under those plans.
The action follows the closing of the merger with Quanterix Corporation on 8 July 2025, under which Wellfleet Merger Sub, Inc. merged into Akoya, leaving Akoya as a wholly owned subsidiary of Quanterix. Because the company’s independent equity programs have been terminated, the related offerings under the S-8 registrations have also ended, triggering the undertaking to deregister the remaining securities.
The filing is signed on behalf of Akoya by Treasurer Vandana Sriram pursuant to Rule 478, and no additional signatures are required.
Akoya Biosciences, Inc. (AKYA) has filed Post-Effective Amendment No. 1 to five prior Form S-8 registration statements covering a combined 15,413,349 shares that were reserved for issuance under the company’s 2015 and 2021 equity compensation and employee stock purchase plans. The amendment formally withdraws any shares that remain unissued under those plans.
The filing follows the closing of the previously announced merger whereby Wellfleet Merger Sub, Inc., a wholly-owned subsidiary of Quanterix Corporation, merged with and into Akoya on 8 July 2025. Akoya survived the transaction as a wholly-owned subsidiary of Quanterix. Because Akoya is no longer an independent public company, its equity incentive plans and related share offerings have been terminated and the SEC registrations are no longer required.
Operationally, the amendment is an administrative step with no impact on outstanding Akoya shares already converted in the merger. It eliminates potential registration maintenance costs and SEC reporting obligations tied to the now-obsolete plans. The document provides no new financial results, outlook, or merger consideration details—investors should rely on prior merger communications for those specifics.
Akoya Biosciences, Inc. ("Akoya") filed Post-Effective Amendment No. 1 to five previously effective Form S-8 registration statements to deregister any shares that remain unissued under its 2015 and 2021 equity compensation plans.
The action follows the closing of the merger with Quanterix Corporation on 8 July 2025, in which Wellfleet Merger Sub, Inc. was merged with and into Akoya, leaving Akoya as a wholly owned subsidiary of Quanterix. Because Akoya’s stand-alone equity offerings have terminated, the company is withdrawing the following original S-8 share pools:
- Reg. No. 333-285859 – 2,478,606 EIP shares & 247,860 ESPP shares
- Reg. No. 333-277648 – 2,455,886 EIP shares & 245,588 ESPP shares
- Reg. No. 333-270312 – 1,914,409 EIP shares & 191,440 ESPP shares
- Reg. No. 333-263548 – 1,871,205 EIP shares & 187,120 ESPP shares
- Reg. No. 333-255468 – 3,920,487 2015 EIP shares, 1,727,953 2021 EIP shares & 172,795 ESPP shares
This is an administrative filing; it does not affect the merger consideration already received by former Akoya shareholders, nor does it introduce new financial metrics. The amendment is signed by Treasurer Vandana Sriram on behalf of Akoya and relies on Rule 478 to omit additional signatures.
Akoya Biosciences, Inc. (AKYA) has been the subject of a Form 25 filing submitted by Nasdaq Stock Market LLC on 2025-07-08. The Exchange states that it has satisfied the requirements of 17 CFR 240.12d2-2(b), allowing it to strike the company’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies reasonable grounds for the filing and the notification is signed by Tara Petta, AVP. The form also references compliance with the voluntary withdrawal provisions of 17 CFR 240.12d-2(c).
Once effective, Akoya’s shares will no longer trade on Nasdaq and the Section 12(b) registration will terminate, severely reducing exchange-based liquidity and regulatory reporting obligations.
Transaction overview: On July 8, 2025, Akoya Biosciences, Inc. (“Akoya”) completed its merger with Wellfleet Merger Sub, a wholly-owned subsidiary of Quanterix Corporation, becoming a wholly-owned subsidiary of Quanterix pursuant to the Amended and Restated Agreement and Plan of Merger dated April 28, 2025.
Merger consideration: Each Akoya share was converted into (a) 0.1461 share of Quanterix common stock and (b) US $0.38 in cash, with caps that limit Quanterix’s total share issuance to 19.99 % of its pre-closing shares and aggregate cash to US $20 million; fractional shares will be paid in cash. Vested RSUs and in-the-money options were cancelled for the right to receive the same per-share consideration, while unvested RSUs rolled over into Quanterix-settled awards. Underwater options were terminated without payment.
Capital structure changes: Concurrent with closing, Akoya repaid in full and terminated its 2020 MidCap Credit and Security Agreement, ended its 2021 Employee Stock Purchase Plan, and provided notice to terminate its 2022 Equity Distribution Agreement with Piper Sandler. Akoya’s certificate of incorporation and bylaws were amended and restated to match those of the surviving subsidiary.
Listing & reporting status: Akoya requested Nasdaq to suspend trading on July 8, 2025 and will file Form 25 to delist its common stock, followed by Form 15 to terminate Exchange Act registration and reporting obligations.
Governance & management: All pre-merger directors and executive officers resigned. Masoud Toloue became sole director and President; Vandana Sriram (Treasurer), Laurie Churchill (Secretary) and Brian Keane (Assistant Secretary) filled the remaining officer roles.
Investor implications: Shareholders gain immediate liquidity and continued upside through Quanterix equity while Akoya eliminates its outstanding debt. However, AKYA will no longer trade independently, and minority holders’ future value will be tied to Quanterix’s performance.